乳腺癌多药耐药是导致乳腺癌治疗失败的主要原因。PI3K/AKT/mTOR信号通路异常激活与乳腺癌的发生发展及耐药性密切相关,抑制该通路是改善乳腺癌治疗效果和克服耐药的可行途径。目前,许多PI3K/AKT/mTOR信号通路抑制剂通过联合标准疗法克服乳腺癌的多药耐药正处于临床前或临床研究。本文综述了PI3K/AKT/mTOR通路在乳腺癌多药耐药中的作用以及通过抑制该通路克服乳腺癌多药耐药的策略研究。Multidrug resistance of breast cancer is the main cause of treatment failure of breast cancer. The abnormal activation of PI3K/AKT/mTOR signaling pathway is closely related to the occurrence, development and drug resistance of breast cancer. Inhibiting PI3K/AKT/mTOR signaling pathway is an effective way to improve the therapeutic effect of breast cancer and overcome drug resistance. At present, several PI3K/AKT/mTOR signaling pathway inhibitors are in preclinical or clinical research to overcome multidrug resistance of breast cancer. This article reviews the role of PI3K/AKT/mTOR pathway in breast cancer multidrug resistance and the research progress of strategies to overcome breast cancer multidrug resistance by inhibiting this pathway.
三阴性乳腺癌(Triple-Negative Breast Cancer, TNBC)是乳腺癌中最具侵袭性的亚型,由于缺乏雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2 (HER2)的表达,治疗选择相对有限,预后效果较差。肿瘤免疫微环境(TIME)在三阴性乳腺癌的...
详细信息
三阴性乳腺癌(Triple-Negative Breast Cancer, TNBC)是乳腺癌中最具侵袭性的亚型,由于缺乏雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2 (HER2)的表达,治疗选择相对有限,预后效果较差。肿瘤免疫微环境(TIME)在三阴性乳腺癌的发生发展、侵袭转移过程中起着关键作用,对患者的预后具有重要的影响。免疫治疗是三阴性乳腺癌的主要治疗手段之一,针对肿瘤免疫微环境的免疫治疗手段为三阴性乳腺癌的治疗的思路提供了新方向。本文就三阴性乳腺癌的免疫微环境特征及主要免疫治疗进展进行综述。Triple-Negative Breast Cancer (TNBC), the most aggressive subtype of breast cancer, has relatively limited treatment options and poor prognosis due to lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Tumor immune microenvironment (TIME) plays a key role in the occurrence, development, invasion and metastasis of triple-negative breast cancer, and has an important impact on the prognosis of patients. Immunotherapy is one of the main therapeutic methods for triple-negative breast cancer. Immunotherapy targeting the tumor immune microenvironment provides a new direction for the treatment of triple-negative breast cancer. This article reviews the characteristics of the immune microenvironment of triple negative breast cancer and the progress of immunotherapy.
暂无评论